Highlights

  • De.mem (ASX:DEM) traded at AUD 0.105 on 13 November 2026.
  • September-quarter customer receipts were approximately AUD 10.1 million, up 29% year on year.
  • Operating cash flow reached approximately AUD 842,000 in the September quarter.
  • Cash at 30 September was around AUD 4.8 million, up from AUD 4.3 million in June.

De.mem Limited supplies industrial and residential water-treatment products and services, including membrane technology, equipment and specialty chemicals. On 13 November 2026, De.mem (ASX:DEM) was quoted at AUD 0.105. The company’s October 2026 September-quarter report identified higher customer cash receipts and a third consecutive quarter of positive operating cash flow.

Company Business and Customer Markets

De.mem operates in water and wastewater treatment for industrial customers and provides products for domestic filtration applications. Services and specialty chemicals are important recurring elements of its offering, while equipment and membrane sales add project-related income. The company also has operations in Western Australia, where its Core Chemicals business contributes to its chemical distribution and water-treatment activities. Geographic and customer diversity does not eliminate individual contract or integration risks.

For multi-site industrial clients, the company markets treatment services, supplies and equipment together. The recurring nature of consumables and service engagements can support regular receipts, although reported cash may still vary with collection timing and customer activity. De.mem is also developing its residential membrane product business, where commercial adoption and channel arrangements will determine future results.

September 2026 Quarter Developments

De.mem reported approximately AUD 10.1 million cash receipts in the September quarter, 29% higher than the corresponding 2025 period. That was described as its second-highest quarterly receipts level. For the nine months ended September 2026, cash receipts were around AUD 30.1 million, 28% above the comparable period. The company said it had achieved 30 consecutive quarters of year-on-year growth in quarterly cash receipts.

The quarterly release also highlighted a new specialty-chemicals Supply contract with an Australian Mining customer and water-treatment equipment orders in Australia and Germany. These orders indicate activity across product lines, but they should not be counted as recognised Revenue until the applicable reporting conditions have been met. The company attributed contributions in Western Australia partly to its Core Chemicals Acquisition and subsequent customer activity.

Financial Performance and Sector Context

Net Operating Cash Flow was approximately AUD 842,000 for the September quarter, compared with AUD 424,000 in June and AUD 504,000 in March 2026. Combined operating cash flow for the first nine months was approximately AUD 1.77 million. The cash balance reached around AUD 4.8 million at 30 September, compared with AUD 4.3 million at the end of June. These numbers indicate reported cash generation, but are not substitutes for statutory profit and revenue figures.

De.mem stated that more than 90% of receipts were recurring in nature. Its commentary indicated that the Western Australian businesses, including Core Chemicals, accounted for approximately 47% of quarterly group receipts. Exposure to industrial water requirements supports Demand for treatment, while Capital spending, procurement cycles and chemical input costs may alter customer volumes and margins. No specific revenue forecast should be inferred from cash-receipts growth alone.

Risks and Upcoming Monitoring Points

Operational considerations include maintaining customer contracts, integrating acquired operations, supply and chemical pricing, and converting new product orders into fulfilled sales. Domestic membrane products also face commercialisation and distribution requirements. Positive cash flow in one period may not be repeated in every quarter because Working Capital and project receipts can move between reporting dates.

The December 2026 quarter will provide the next comparable receipts and operating cash-flow figures, as well as information about the timing of new contracts. De.mem (ASX:DEM) has referred to its 2026 outlook in favourable terms, but the quantified September results remain the firmer basis for assessing progress. Investors can also monitor cash reserves and the contribution of recurring services relative to equipment sales.

Key Insights

De.mem (ASX:DEM) reported higher September-quarter receipts, positive operating cash flow and an increased quarter-end cash balance. The mix of recurring industrial services, chemicals and membrane-related products remains central to its business. Subsequent disclosures will show whether cash generation, customer demand and acquisition-related activity continue to support its operating model.